Stock Scorecard
Stock Summary for Pasithea Therapeutics Corp (KTTA) - $0.72 as of 10/25/2025 3:09:08 AM EST
Total Score
13 out of 30
Safety Score
24 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KTTA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KTTA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KTTA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KTTA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for KTTA (24 out of 100)
| Stock Price Rating (Max of 10) | 1 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 1 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for KTTA
Financial Details for KTTA
Company Overview |
|
|---|---|
| Ticker | KTTA |
| Company Name | Pasithea Therapeutics Corp |
| Country | USA |
| Description | Pasithea Therapeutics Corp. (KTTA) is a Miami Beach-based biopharmaceutical company dedicated to developing innovative therapeutics targeting psychiatric and neurological disorders through psychedelic compounds. The company aims to address significant unmet medical needs, positioning itself as a leader within the burgeoning field of mental health treatments. With a robust commitment to clinical research and development, Pasithea's proprietary platform not only seeks to enhance patient outcomes but also indicates strong potential for long-term growth and value creation in the healthcare sector. As it navigates this evolving landscape, Pasithea stands poised to make impactful contributions to mental health solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 0.72 |
| Price 4 Years Ago | 35.40 |
| Last Day Price Updated | 10/25/2025 3:09:08 AM EST |
| Last Day Volume | 15,777 |
| Average Daily Volume | 92,839 |
| 52-Week High | 4.35 |
| 52-Week Low | 0.65 |
| Last Price to 52 Week Low | 10.77% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.93 |
| Sector PE | 41.00 |
| 5-Year Average PE | -56.50 |
| Free Cash Flow Ratio | 0.74 |
| Industry Free Cash Flow Ratio | 14.60 |
| Sector Free Cash Flow Ratio | 29.25 |
| Current Ratio Most Recent Quarter | 4.97 |
| Total Cash Per Share | 0.97 |
| Book Value Per Share Most Recent Quarter | 2.04 |
| Price to Book Ratio | 0.39 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.16 |
| Price to Sales Ratio Twelve Trailing Months | 42.15 |
| Industry Price to Sales Ratio Twelve Trailing Months | 33.22 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.80 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 7,443,600 |
| Market Capitalization | 5,359,392 |
| Institutional Ownership | 11.17% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 12.89% |
| Reported EPS 12 Trailing Months | -7.13 |
| Reported EPS Past Year | -2.27 |
| Reported EPS Prior Year | -12.81 |
| Net Income Twelve Trailing Months | -13,456,890 |
| Net Income Past Year | -13,904,584 |
| Net Income Prior Year | -15,961,658 |
| Quarterly Revenue Growth YOY | 1,498.00% |
| 5-Year Revenue Growth | 468.36% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 7,217,052 |
| Total Cash Past Year | 6,922,729 |
| Total Cash Prior Year | 16,331,052 |
| Net Cash Position Most Recent Quarter | 7,217,052 |
| Net Cash Position Past Year | 6,922,729 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 14,782,676 |
| Total Stockholder Equity Prior Year | 23,398,452 |
| Total Stockholder Equity Most Recent Quarter | 15,178,445 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -3,065,189,373 |
| Free Cash Flow Per Share Twelve Trailing Months | -411.79 |
| Free Cash Flow Past Year | -13,923 |
| Free Cash Flow Prior Year | -13,459,712 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.01 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.67 |
| 20-Day Bollinger Middle Band | 0.74 |
| 20-Day Bollinger Upper Band | 0.81 |
| Beta | 0.27 |
| RSI | 45.25 |
| 50-Day SMA | 5.96 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 10.30 |
System |
|
| Modified | 10/25/2025 3:09:10 AM EST |